Yunnan Baiyao responded that it lost 1.5 billion in stock speculation: it will gradually optimize the structure and gradually withdraw from securities investment

Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows

A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?

Pulnovo Medical: Chinese Medical Device Companies are Making Their Voices Heard Globally

‘Chinese medical device companies, represented by Pulnovo Medical, have always pursued medical innovation under the support of policies and capital. They have increasingly improved their technical innovation, strategic planning, and product competitiveness. Navigating the way through a dynamic, ever-changing market, Chinese medical device companies are making their voices heard in the global market.’

Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021

On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.

Yunnan Baiyao: An Oriental Mystery in the Limelight (2/2)

Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.

Yunnan Baiyao: An Oriental Mystery in the Limelight (1/2)

Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.